Cetuximab and panitumumab for previously untreated metastatic colorectal cancer

Equality Impact Assessment (Guidance development) (PDF 305 KB)

Final appraisal determination

Final appraisal determination document (PDF 152 KB)

Committee papers (PDF 6.48 MB)

Public committee slides (PDF 648 KB)

Draft guidance: 1

Appraisal consultation document (PDF 226 KB)

Committee papers (PDF 8.36 MB)

Assessment report (PDF 4.52 MB)

Final scope (PDF 40 KB)

Final matrix (PDF 51 KB)

Comments table (PDF 56 KB)

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): final protocol (PDF 139 KB)

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): equality impact assessment scoping (PDF 14 KB)

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): provisional matrix (PDF 35 KB)

Colorectal cancer (metastatic) - cetuximab (review TA176) and panitumumab (part review TA240) (1st line): draft scope (PDF 38 KB)